




RealRate

PHARMACEUTICAL 2022

Phathom Pharmaceuticals Inc
Rank 385 of 471

Phathom.
PHARMACEUTICALS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Phathom Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Phathom Pharmaceuticals Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 9.0% points. The greatest weakness of Phathom Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 132% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 125% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	186,526
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,921
Liabilities, Non-Current	98,354
Other Assets	2,255
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-8,803
Other Revenues	0
Property and Equipment	650
Research and Development	72,338
Selling, General and Administrative Expense	62,742

Output Variable	Value in 1000 USD
Assets	189,431
Liabilities	117,275
Expenses	135,080
Revenues	0
Stockholders Equity	72,156
Net Income	-143,883
Comprehensive Net Income	-143,883
BaseVar	225,294
ECR before Limited Liability	8.7%
Economic Capital Ratio	150%